Faltering Vaccine Supplies in India Is Bad News for the World
Ivana Kottasova
4/20/2021 2:53:32 PM
Ivana Kottasová wrote the following article in CNN:
The world's biggest vaccine producer is running out of Covid-19 shots as it struggles to keep pace with a huge surge in new infections.
India typically produces more than 60% of all vaccines sold globally, and is home to the Serum Institute of India (SII), the globe's largest vaccine maker.
This vast manufacturing capability is why the country is a major player in COVAX, the global vaccine-sharing initiative that provides discounted or free doses for lower-income countries.
Under an initial agreement announced last year, the SII would manufacture up to 200 million doses for up to 92 countries. But the situation in India has changed dramatically since then, Jessie Yeung and Esha Mitra write.
A second pandemic wave that began in March has quickly surpassed the first in terms of case numbers. On Monday, the country reported almost 274,000 new infections, its highest single-day figure so far, and 1,619 new deaths, the highest in almost 10 months. It has recorded more than 1 million cases in the past five days alone and topped 15 million total cases on Monday, second only to the United States globally.
States and cities are imposing new restrictions, including weekend and nighttime curfews in the capital region of Delhi, home to 19 million people.
Through it all, vaccine supplies have dried up on the ground, with at least five states reporting severe shortages and urging India's federal government to act. To date, only 14.3 million people have been fully vaccinated -- just over 1% of the country's population of 1.3 billion, according to Johns Hopkins University.
In the face of crisis, the government and SII have shifted focus from supplying vaccines to COVAX to prioritizing their own citizens at home.
Subsequent delays will hit developing countries that were expecting deliveries. The director of Africa's disease control body warned India's hold on exports could be "catastrophic" for the continent, while Pakistan, one of the biggest program recipients, decided to allow private vaccine imports and sales to fill the gap.
The world's biggest vaccine producer is running out of Covid-19 shots as it struggles to keep pace with a huge surge in new infections.
India typically produces more than 60% of all vaccines sold globally, and is home to the Serum Institute of India (SII), the globe's largest vaccine maker.
This vast manufacturing capability is why the country is a major player in COVAX, the global vaccine-sharing initiative that provides discounted or free doses for lower-income countries.
Under an initial agreement announced last year, the SII would manufacture up to 200 million doses for up to 92 countries. But the situation in India has changed dramatically since then, Jessie Yeung and Esha Mitra write.
A second pandemic wave that began in March has quickly surpassed the first in terms of case numbers. On Monday, the country reported almost 274,000 new infections, its highest single-day figure so far, and 1,619 new deaths, the highest in almost 10 months. It has recorded more than 1 million cases in the past five days alone and topped 15 million total cases on Monday, second only to the United States globally.
States and cities are imposing new restrictions, including weekend and nighttime curfews in the capital region of Delhi, home to 19 million people.
Through it all, vaccine supplies have dried up on the ground, with at least five states reporting severe shortages and urging India's federal government to act. To date, only 14.3 million people have been fully vaccinated -- just over 1% of the country's population of 1.3 billion, according to Johns Hopkins University.
In the face of crisis, the government and SII have shifted focus from supplying vaccines to COVAX to prioritizing their own citizens at home.
Subsequent delays will hit developing countries that were expecting deliveries. The director of Africa's disease control body warned India's hold on exports could be "catastrophic" for the continent, while Pakistan, one of the biggest program recipients, decided to allow private vaccine imports and sales to fill the gap.